RESUMEN
INTRODUCTION: Missense variants and multiplications of the alpha-synuclein gene (SNCA) are established as rare causes of autosomal dominant forms of Parkinson's Disease (PD). METHODS: Two families of Turkish origins with PD were studied; the SNCA coding region was analyzed by Sanger sequencing, and by whole exome sequencing (WES) in the index patient of the first and the second family, respectively. Co-segregation studies and haplotype analysis across the SNCA locus were carried out. Functional studies included in vitro thioflavin-T aggregation assay and in silico structural modelling of the alpha-synuclein (α-syn) protein. RESULTS: We identified a novel heterozygous SNCA variant, c.215C > T (p.Thr72Met), segregating with PD in a total of four members in the two families. A shared haplotype across the SNCA locus was found among variant carriers, suggestive of a common ancestor. We next showed that the Thr72Met α-syn displays enhanced aggregation in-vitro, compared to the wild-type species. In silico analysis of a tetrameric α-syn structural model revealed that Threonine 72 lies in the tetrameric interface, and substitution with the much larger methionine residue could potentially destabilize the tetramer. CONCLUSION: We present clinical, genetic, and functional data supporting a causative role of the SNCA c.215C > T (p.Thr72Met) variant in familial PD. Testing for this variant in patients with PD, especially of Turkish origin, might detect additional carriers. Further functional analyses might offer new insights into the shared biochemical properties of the PD-causing SNCA missense variants, and how they lead to neurodegeneration.
Asunto(s)
Enfermedad de Parkinson/genética , Enfermedad de Parkinson/fisiopatología , alfa-Sinucleína/genética , Femenino , Haplotipos , Humanos , Persona de Mediana Edad , Linaje , TurquíaAsunto(s)
Aspergillus fumigatus/inmunología , Calcineurina/metabolismo , Inmunidad Innata , Macrófagos/inmunología , Modelos Inmunológicos , Infecciones Oportunistas/inmunología , Aspergilosis Pulmonar/inmunología , Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/patogenicidad , Aspergillus fumigatus/fisiología , Calcineurina/química , Inhibidores de la Calcineurina/uso terapéutico , Señalización del Calcio/efectos de los fármacos , Rechazo de Injerto/inmunología , Rechazo de Injerto/metabolismo , Rechazo de Injerto/microbiología , Rechazo de Injerto/prevención & control , Humanos , Inmunidad Innata/efectos de los fármacos , Inmunosupresores/uso terapéutico , Macrófagos/efectos de los fármacos , Macrófagos/microbiología , Macrófagos/patología , Factores de Transcripción NFATC/metabolismo , Necrosis , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/metabolismo , Infecciones Oportunistas/microbiología , Trasplante de Órganos/efectos adversos , Fagocitosis/efectos de los fármacos , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/inmunología , Complicaciones Posoperatorias/metabolismo , Complicaciones Posoperatorias/microbiología , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/metabolismo , Aspergilosis Pulmonar/microbiologíaRESUMEN
Endosomal sensing represents a key strategy by which mammalian cells detect parasitization by invading pathogens. This is critical for the control of fungal pathogens, which are for the most part phagocytosed by effector cells of the innate immune system. Despite rapid overall progress in our understanding of endosomal responses in recent times, relatively little is known about how the endosomal sensing system detects fungi and the ensuing immunological consequences. Considering that many fungal pathogens must overcome and evade endosomal killing in order to survive in the host, understanding this key area of the early innate response is crucial for our understanding of fungal infection. In this review we present a summary of our current knowledge of endosomal sensing within the context of fungal pathogens, with a focus on the myeloid compartment.
Asunto(s)
Endosomas/microbiología , Hongos/crecimiento & desarrollo , Hongos/inmunología , Interacciones Huésped-Patógeno , Animales , Investigación Biomédica/tendencias , Humanos , Evasión Inmune , Mamíferos , Viabilidad Microbiana , FagocitosisRESUMEN
Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1- and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85 - 7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08 - 5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.